Search hospitals > Michigan > Chelsea

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Claim this profile
Chelsea, Michigan 48118
Global Leader in Skin Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
205 reported clinical trials
7 medical researchers
Photo of Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital in ChelseaPhoto of Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital in ChelseaPhoto of Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital in Chelsea

Summary

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is a medical facility located in Chelsea, Michigan. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is involved with conducting 205 clinical trials across 359 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.

Area of expertise

1Skin Cancer
Global Leader
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital has run 91 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital has run 41 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Breast Cancer
Lung Cancer
Skin Cancer
Breast cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Multiple Myeloma
Stomach Cancer
Esophageal Adenocarcinoma
Bladder Cancer
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital?
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is a medical facility located in Chelsea, Michigan. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is involved with conducting 205 clinical trials across 359 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security